Loading...
Clinical activity of ASP8273 in Asian patients with non‐small‐cell lung cancer with EGFR activating and T790M mutations
Epidermal growth factor receptor (EGFR)‐activating mutations confer sensitivity to tyrosine kinase inhibitor (TKI) treatment for non‐small‐cell lung cancer (NSCLC). ASP8273 is a highly specific, irreversible, once‐daily, oral, EGFR TKI that inhibits both activating and resistance mutations. This ASP...
Na minha lista:
| Udgivet i: | Cancer Sci |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6125469/ https://ncbi.nlm.nih.gov/pubmed/29972716 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13724 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|